This database contains 524 studies, archived under the term: "alzheimer disease"
Click here to filter this large number of results.
Postoperative medical complications associated with anesthesia in older adults with dementia
Seitz, Dallas P.,
Gill, Sudeep S.,
Bell, Chaim M.,
Austin, Peter C.,
Gruneir, Andrea,
Anderson, Geoff M.,
Rochon, Paula A.
Objectives: To examine the association between anesthetic technique and postoperative complications in older adults with dementia undergoing hip fracture surgery.; Design: Population-based, retrospective cohort study.; Setting: Ontario, Canada.; Participants: All older adults with dementia who underwent surgery for hip fracture repair in Ontario, Canada, between April 1, 2003 and March 31, 2011.; Measurements: The baseline […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]
Measuring the experience and perception of suffering
Schulz, R.,
Monin, J. K.,
Czaja, S. J.,
Lingler, J. H.,
Beach, S. R.,
Martire, L. M.,
Dodds, A.,
Hebert, R. S.,
Zdaniuk, B.,
Cook, T. B.
Purpose: assess psychometric properties of scales developed to assess experience and perception of physical, psychological, and existential suffering in older individuals.; Design and Methods: scales were administered to 3 populations of older persons and/or their family caregivers: individuals with Alzheimer’s disease (AD) and their family caregivers (N = 105 dyads), married couples in whom 1 […]
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
Schöll, Michael,
Almkvist, Ove,
Axelman, Karin,
Stefanova, Elka,
Wall, Anders,
Westman, Eric,
Långström, Bengt,
Lannfelt, Lars,
Graff, Caroline,
Nordberg, Agneta
Six young related pre-symptomatic carriers of a His163Tyr mutation in the presenilin 1 gene who will develop early onset familial Alzheimer’s disease (eoFAD), and a control group of 23 non-carriers underwent (18)F-fluorodeoxyglucose positron emission tomography (FDG PET). The mutation carriers were followed-up after 2 years. Multivariate analysis showed clear separation of carriers from non-carriers on […]
Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria
Schmidt, Reinhold,
Baumhackl, Ulf,
Berek, Klaus,
Brücke, Thomas,
Kapeller, Peter,
Lechner, Anita,
Rainer, Michael,
Stögerer, Eva-Maria
We conducted an open, 16-week study on the efficacy of memantine on behavioral disturbances and psychotic symptoms in moderate to moderately severe Alzheimer s disease in daily routine. Fifty-three patients of 20 outpatient centers in Austria were recruited. The Neuropsychiatric Inventory (NPI) was defined as main outcome measure. After 16 weeks the total NPI score […]
Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial
Scheltens, Philip,
Kamphuis, Patrick J. G. H.,
Verhey, Frans R.J.,
Olde Rikkert, Marcel G. M.,
Wurtman, Richard J.,
Wilkinson, David,
Twisk, Jos W.R.,
Kurz, Alexander
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]
Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice
Sauvée, Mathilde,
DidierLaurent, Guerric,
Latarche, Clotilde,
Escanyé, Marie-Christine,
Olivier, Jean-Luc,
Malaplate-Armand, Catherine
Background: Cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for the diagnosis of Alzheimer’s disease (AD). Since interpretation of CSF profile requires the combination of three parameters, biological data are not always conclusive and isolated elevation of phosphorylated tau (P-tau) or reduction of amyloid-β (Aβ)42 alone can be observed. In these cases, […]